Bringing Novel Gene Therapies to Patients with Rare Diseases

Dimension Therapeutics is a gene therapy company developing novel treatments for rare diseases

Dimension is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics across a wide array of single-gene rare diseases.

Read More

SEPTEMBER 16, 2014
Dimension Therapeutics Names Annalisa Jenkins as Chief Executive Officer

Read More

JUNE 23, 2014
Dimension Therapeutics and Bayer HealthCare Enter Collaboration to Develop Novel Gene Therapy for Hemophilia A

Read More